11/26
06:43 am
pavm
PAVmed (NASDAQ:PAVM) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
PAVmed (NASDAQ:PAVM) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/13
11:37 am
pavm
PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/13
08:31 am
pavm
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum [Yahoo! Finance]
Medium
Report
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum [Yahoo! Finance]
11/13
08:00 am
pavm
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
Medium
Report
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
11/12
08:37 am
pavm
PAVmed Inc (PAVM) Q3 2025 Earnings Report Preview: What to Expect [Yahoo! Finance]
High
Report
PAVmed Inc (PAVM) Q3 2025 Earnings Report Preview: What to Expect [Yahoo! Finance]
11/12
08:19 am
pavm
PAVmed Non-GAAP EPS of -$0.10, revenue of $1.21M [Seeking Alpha]
High
Report
PAVmed Non-GAAP EPS of -$0.10, revenue of $1.21M [Seeking Alpha]
10/30
08:01 am
pavm
PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025
Medium
Report
PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025
10/11
06:14 am
pavm
PAVmed (NASDAQ:PAVM) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
High
Report
PAVmed (NASDAQ:PAVM) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/7
08:01 am
pavm
PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement
Low
Report
PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement
10/6
08:09 am
pavm
PAVmed (NASDAQ:PAVM) had its price target raised by analysts at Ascendiant Capital Markets from $19.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
PAVmed (NASDAQ:PAVM) had its price target raised by analysts at Ascendiant Capital Markets from $19.00 to $20.00. They now have a "buy" rating on the stock.
9/11
09:41 am
pavm
Lucid Diagnostics Announces Closing of Public Offering of Common Stock [Yahoo! Finance]
Low
Report
Lucid Diagnostics Announces Closing of Public Offering of Common Stock [Yahoo! Finance]